Understanding how certain cancer-related gene changes affect treatment response
Functional Characterization of HER Family Variant Biology and Resistance in Cancer
This study is looking at how certain genetic changes in proteins related to cancer might affect treatment options, so if you have a tumor with these changes, it could help you understand which therapies might work best for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10927429 on NIH RePORTER |
What this research studies
This research investigates the role of specific genetic changes in the HER family of proteins, which are often altered in various cancers. By using advanced techniques in functional genomics and molecular biology, the study aims to determine whether these genetic variants contribute to cancer development and how they affect the effectiveness of targeted therapies. Patients with tumors harboring these variants may gain insights into their treatment options based on the functional characteristics of their specific mutations. The goal is to improve patient care by identifying which patients are likely to benefit from existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients with identified HER family gene variants, particularly those with EGFR or HER2 mutations.
Not a fit: Patients without HER family gene variants or those with cancers not involving these specific mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized cancer treatments by identifying which patients will respond to specific therapies based on their genetic makeup.
How similar studies have performed: Previous research has shown success in characterizing genetic variants in cancer, suggesting that this approach could yield valuable insights into treatment resistance.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Hayes, Tikvah K — University of California Los Angeles
- Study coordinator: Hayes, Tikvah K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.